Royal Bank of Canada initiated coverage on shares of Contineum Therapeutics (NASDAQ:CTNM – Free Report) in a report published on Tuesday, MarketBeat.com reports. The brokerage issued an outperform rating and a $30.00 target price on the stock.
A number of other brokerages have also weighed in on CTNM. Morgan Stanley began coverage on shares of Contineum Therapeutics in a research note on Tuesday. They issued an overweight rating and a $25.00 price target on the stock. Stifel Nicolaus began coverage on shares of Contineum Therapeutics in a research note on Tuesday. They issued a buy rating and a $29.00 target price on the stock.
Get Our Latest Stock Report on Contineum Therapeutics
Contineum Therapeutics Stock Down 2.5 %
About Contineum Therapeutics
Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).
Recommended Stories
- Five stocks we like better than Contineum Therapeutics
- What Are Dividend Challengers?
- NXP Semiconductors Will Set a New High Soon: $300 in Sight
- What are earnings reports?
- Hilton Demonstrates Asset Light is Right for Investors
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Receive News & Ratings for Contineum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Contineum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
